6. Al-Sawaf O, et al. J Clin Oncol. 2021 Dec 20;39(36):4049-4060. 7. NCCN Guidelines CLL/SLL Version 1.2024 8. Miao Y, Sha Y, Xia Y, et al. Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in...
12. NCCN Guidelines. Version 2.2022. 13. Fischer K, et al. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ...
A.2; Paik, J.2; Shadman, M.11,12. P662: PATIENT-REPORTED OUTCOMES FROM A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VERSUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN PATIENTS WITH TREATMENT-NAÏVE (TN) CLL/SLL. HemaSphere
[5]Hallek M, Cheson BD, Catovsky D,et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14. PMID: 29540348. [6]Wierda WG, Raws...
[9] Annals of Oncology, Marginal Zone Lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, January 6, 2020.[10] Cerhan, J.R. and T.M. Habermann, Epidemiology of Marginal Zone Lymphoma. Ann Lymphoma, 2021.[11] Smith, A., et al., Lymphoma incidence, ...
在此次获批之前,泽布替尼已于2020年6月获NMPA附条件批准用于治疗既往至少接受过一种治疗的成人套细胞淋巴瘤(MCL)患者和既往至少接受过一种治疗的成人CLL/SLL患者,并于2021年6月获NMPA附条件批准用于治疗既往至少接受过一种治疗的成人WM患者。这些获批适应症已全部被纳入国家医保药品目录。
[9] Annals of Oncology, Marginal Zone Lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, January 6, 2020. [10] Cerhan, J.R. and T.M. Habermann, Epidemiology of Marginal Zone Lymphoma. Ann Lymphoma, 2021. ...
Maleswith female partners who are able to become pregnant should use effective birth control, such as condoms, during treatment with IMBRUVICA® and for 1 month after the last dose. are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with IMBRUVICA® and for 1 week...
CALQUENCE® (acalabrutinib) is a BTK inhibitor indicated for the treatment of adult patients with R/R Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
Conclusions: The use of first ‐ line ibrutinib treatment led to sustained PFS, including for pts with high ‐ risk genomic features, and OS benefit for pts with CLL/SLL with extended long ‐ term follow ‐ up in RESONATE ‐ 2. Over time, responses continue to deepen. Rates of grade ≥...